Chimerix Inc. | Mutual Funds
Mutual Funds that own Chimerix Inc.
Fidelity Select Biotechnology Portfolio
1,871,867
3.92%
0
0.08%
07/31/2018
Meridian Small Cap Growth Fund
1,603,648
3.36%
0
0.39%
03/31/2018
Vanguard Total Stock Market Index Fund
1,183,665
2.48%
52,800
0%
07/31/2018
Fidelity Growth Company Fund
1,169,627
2.45%
-66,038
0.01%
07/31/2018
iShares Russell 2000 ETF
948,912
1.99%
-507
0.01%
09/06/2018
Vanguard Extended Market Index Fund
629,502
1.32%
0
0%
07/31/2018
iShares Nasdaq Biotechnology ETF
550,695
1.14%
-7,203
0.02%
09/06/2018
DFA US Small Cap Portfolio
430,318
0.9%
60,454
0.01%
04/30/2018
iShares Russell 2000 Value ETF
410,312
0.86%
0
0.02%
09/06/2018
DFA US Targeted Value Portfolio
390,590
0.82%
31,569
0.01%
04/30/2018
| Address |
2505 Meridian Parkway
Durham North Carolina 27713
United States
|
|
Employees
|
- |
| Website |
http://www.chimerix.com |
| Updated |
07/08/2019 |
| Chimerix, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes Brincidofovir for the treatment of adenovirus, cytomegalovirus, and smallpox. The company was founded by George R. |
